Images List Premium Download Classic

Obesity

Obesity-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat ...
University Of Copenhagen
June 22, 2017 - N°20170173099

The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and ...
Intragastric device with expandable portions
Obalon Therapeutics, Inc.
June 22, 2017 - N°20170172778

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.
Esculentin-2cha peptide and analogues thereof
University Of Ulster
June 15, 2017 - N°20170166614

The present invention relates to an esculentin-2cha peptide and analogues thereof, and the use each thereof in the treatment of diabetes, for example type 2 diabetes; insulin resistance; obesity, and/or hypercholesterolemia. Also disclosed is a pharmaceutical composition comprising peptides and analogues according to the present invention; use of peptides and analogues according to the present invention for the manufacture ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Heteroaromatic compounds and their use as dopamine d1 ligands
Merck Sharp & Dohme Corp.
June 15, 2017 - N°20170165270

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) and the uses of such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) for the treatment of ...
Method and instrument for treating obesity
Merck Sharp & Dohme Corp.
June 15, 2017 - N°20170165092

A gastroscopic method of treating obesity of a patient using a device adapted to stretch a part of the stomach wall of said patient. The method comprising the steps of: inserting said device into the stomach of said patient through the esophagus, placing said device in contact with the stomach wall and fixating said device to the stomach wall such ...
Compositions comprising cinnamaldehyde and zinc and methods of using such compositions
Nestec S.a.
June 15, 2017 - N°20170164648

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Composition of plant extract and its pharmaceutical composition and application thereof
Caliway Biopharmaceuticals Co., Ltd.
June 08, 2017 - N°20170157194

Provided is a plant extract composition and a pharmaceutical composition thereof for reducing body weight and body fat, wherein the plant extract composition comprises a green tea extract and a turmeric extract respectively 30 wt % to 75 wt % and 20 wt % to 55 wt % of a total weight of the composition. In diet-induced obesity models, either obesity is induced first or simultaneously with administration, ...
Intragastric device
Obalon Therapeutics, Inc.
June 08, 2017 - N°20170156909

Devices and methods for treating obesity are provided. More particularly, intragastric devices and devices for inflating and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.
Inhibitors of the farnesoid x receptor and uses in medicine
The Penn State Research Foundation
June 01, 2017 - N°20170152283

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier ...
Technology and methods of on-board vehicle occupant accurate weighing by a simplified weighing apparatus based ...
The Penn State Research Foundation
June 01, 2017 - N°20170151892

An on-board vehicle occupant weighing technology includes a simplified vehicle occupant weighing apparatus based on the discovered horwest effect and weighing moderator. The simplified weighing apparatus utilizes a weighing unit connected to the car seat of the vehicle occupant and a further weighing moderator, which provides convenient weighing of the foot part of the occupant's body by the same weighing ...
Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial ...
New York University
June 01, 2017 - N°20170151290

The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (hpmc) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow ...
Low dose topiramate/phentermine composition and methods of use thereof
Vivus, Inc.
June 01, 2017 - N°20170151179

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated ...
Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
Vivus, Inc.
May 25, 2017 - N°20170145000

The present invention relates to canagliflozin monohydrate and its crystalline forms. Compared to the prior art, canagliflozin monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability. The present invention also relates to preparation methods of canagliflozin monohydrate and its crystalline forms, ...
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
Vivus, Inc.
May 25, 2017 - N°20170143779

The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an aav virion comprising an aav vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are aav vectors and aav ...
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
Vivus, Inc.
May 25, 2017 - N°20170143667

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ...
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
Vivus, Inc.
May 25, 2017 - N°20170143666

Provided are compositions comprising compounds or precursors to compounds which may be used for a. Variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ...
Devices and methods for endolumenal treatment of obesity
Vivus, Inc.
May 25, 2017 - N°20170143524

Devices and methods for forming and securing tissue folds and elongated invaginations in stomach tissue are used as a treatment for obesity. In a first embodiment, a plurality of tissue folds is formed in the fundus region of the stomach. In methods for surgically altering stomach tissue to change gastric emptying, plications are formed in the stomach to speed up ...
Stomach-spanning gastric implants
Vivus, Inc.
May 25, 2017 - N°20170143523

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive implants do not autonomously change shape, but instead react within the stomach to induce satiety. The implants may take up volume within the stomach, thus reducing the digestive capacity. Additionally, the implants may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, ...
Organic compositions to treat apoc3-related diseases
Arrowhead Pharmaceuticals, Inc.
May 18, 2017 - N°20170137814

The present disclosure relates to compositions and methods for treating apoc3-related diseases such as: hypertriglyceridemia (e. G., type v hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a rnai agent to apoc3.
Long-acting single-chain insulin analogues
Case Western Reserve University
May 18, 2017 - N°20170137488

A single-chain insulin analogue containing a basic side chain at position a8 (arginine, histidine, lysine, or ornithine), a basic side chain at position b29 (arginine, histidine, lysine, or ornithine), and a foreshortened c-domain of length 6-11 residues is provided. Residues c1 and c2 of the c-domain have a net negative charge of −1 or −2; c3 is chosen from a ...
Peptide yy (pyy) analogues
Imperial Innovations Limited
May 18, 2017 - N°20170137486

Analogues of peptide yy (pyy), which are useful in treating disorders such as diabetes and obesity and also for inducing cosmetic weight loss, related compositions, formulations, uses and methods.
Loading